Vascugen Inc is a regenerative medicine company based in Indianapolis, IN, dedicated to developing innovative therapies for vascular diseases that do not respond to standard treatments. Their focus is on utilizing induced pluripotent stem cell (iPSC) technology to manufacture regenerative medicine products that can restore function in tissues with a loss of blood flow. With a mission to address refractory conditions and improve the lives of patients, Vascugen aims to translate their discoveries into potent treatments for a range of vascular degenerative conditions.
Vascugen's unique approach involves directly restoring blood flow by forming new blood vessels, known as vasculogenesis, rather than relying on indirect mechanisms like growth factors and mesenchymal cells. Their research has shown promising results in animal models of ischemic injury, and they are particularly focused on developing therapies for critical limb ischemia (CLI) and diabetic retinopathy (DR). By targeting these severe forms of vascular disease, Vascugen aims to provide new interventions and improve outcomes for patients who currently have limited treatment options.
Generated from the website